Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC ‐3G3) to patients with advanced soft tissue sarcoma

ConclusionsOlaratumab at 15 or 20  mg/kg before doxorubicin infusion had no clinically relevant effect on systemic exposure to doxorubicin compared with doxorubicin alone in patients with metastatic or locally advanced STS.

Source: Cancer Medicine - December 9, 2019 Category: Cancer & Oncology Authors: Victor M. Villalobos, Gary Mo, Mark Agulnik, Seth M. Pollack, Daniel A. Rushing, Arun Singh, Brian A. Van Tine, Rhian McNaughton, Rodney L. Decker, Wei Zhang, Ashwin Shahir, Damien M. Cronier Tags: ORIGINAL RESEARCH Source Type: research